FOLFIRI

From Wikipedia, the free encyclopedia
Jump to: navigation, search

FOLFIRI is a chemotherapy regimen for treatment of colorectal cancer. It is made up of the following drugs:

  • FOL – folinic acid (leucovorin), a vitamin B derivative used as a "rescue" drug for high doses of the drug methotrexate, but increases the cytotoxicity of 5-fluorouracil;
  • F – fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops synthesis; and
  • IRI – irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating.

Medical uses[edit]

FOLFIRI is used for colorectal cancer and gastric cancer.[1] FOLFIRI is effective in the treatment of metastatic colorectal cancer, but it has not been shown to be effective in the adjuvant treatment of colon and rectal cancer.

Regimen[edit]

The regimen consists of:

  • Irinotecan (180 mg/m² IV over 90 minutes) concurrently with folinic acid (400 mg/m² [or 2 x 250 mg/m²] IV over 120 minutes).
  • Followed by fluorouracil (400–500 mg/m² IV bolus) then fluorouracil (2400–3000 mg/m² intravenous infusion over 46 hours).

This cycle is typically repeated every two weeks. The dosages shown above may vary from cycle to cycle.

FOLFIRI Combinations[edit]

FOLFIRI is often combined with bevacizumab, aflibercept, cetuximab or panitumumab to improve efficacy and response rate.

Adverse Effects[edit]

In the short term, Irinotecan causes diarrhea, which may be acute or delayed in onset. The long term use of Irinotecan may lead to neutropenia.

See also[edit]

References[edit]

  1. ^ Tournigand, C; André, T; Achille, E; Lledo, G; Flesh, M; Mery-Mignard, D; Quinaux, E; Couteau, C; Buyse, M; Ganem, G; Landi, B; Colin, P; Louvet, C; de Gramont, A (Jan 15, 2004). "FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.". Journal of clinical oncology : official journal of the American Society of Clinical Oncology 22 (2): 229–37. PMID 14657227.